Highlights Innovation Pharmaceuticals Inc.

Equities

IPIX

US45782D1000

Market Closed - OTC Markets Other stock markets 17:49:53 10/05/2024 BST			5-day change	1st Jan Change
0.0008 ^USD	+14.29%		-61.90%	-83.67%

02-01	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
2023	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	12-05	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-20	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/09/23	CI
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	21/06/23	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	15/05/23	CI
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers	15/03/23	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	15/02/23	CI
Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin	13/12/22	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	10/11/22	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	28/09/22	CI
INNOVATION PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	15/06/22	AQ
Innovation Pharmaceuticals Inc. acquired an unknown minority stake in Squalus Medical.	14/06/22	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	13/05/22	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	14/02/22	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	09/11/21	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	27/09/21	CI
Innovation Pharmaceuticals Provides Additional Information Regarding the Status of Its Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of Brilacidin for the Treatment of Moderate-To-Severe Covid-19 in Hospitalized Patients	12/08/21	CI
Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting	22/07/21	CI
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium	18/06/21	CI
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19	03/06/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Innovation Pharmaceuticals Inc.

Equities

IPIX

US45782D1000

Highlights

Filters